Lotte Biologics to Participate in CPHI Germany... Targeting the Global CDMO Market

Lotte Biologics announced on the 27th that it will participate in "CPHI Worldwide," which will be held from October 28 to 30 (local time) in Frankfurt, Germany.

Lotte Biologics Exclusive Exhibition Booth at CPHI Worldwide. Lotte Biologics

This marks the fourth time Lotte Biologics has participated in "CPHI Worldwide," the world's largest pharmaceutical and biotechnology conference, which began in 1990 and is held annually in major European cities. This year's event is expected to attract more than 2,400 companies and over 60,000 visitors from around the world, making it a vibrant hub for global pharmaceutical and biotechnology industry exchanges.

On the first day of the event, Jang Gunhee, Head of Technology Development, will speak at the Antibody-Drug Conjugate (ADC) seminar session, presenting on the topic "Lotte Biologics ADC Platform: Accelerating Bio-Conjugate Development and Production," highlighting the competitiveness of Lotte Biologics' ADC manufacturing facilities.

On the same day at the exhibition booth, Jang Junyoung, Head of Global Business Development, will deliver an In Booth Presentation, emphasizing the advantages of the Dual Site strategy and the operational strengths of the 5,000-liter bioreactor at the Syracuse Bio Campus, as well as the company's proven quality competitiveness. On the second day, Jang Gunhee will also give an In Booth Presentation to general visitors, showcasing Lotte Biologics' differentiated competitiveness as a global ADC CDMO (Contract Development and Manufacturing Organization).

A variety of events will also be held to further expand customer engagement. In the "Event Zone" within the exhibition booth, a dart game event symbolizing an ADC targeting cancer cell antigens will take place. On the afternoons of the first and second days, a "Happy Hour Event" is scheduled to coincide with the In Booth Presentation times. During these periods, visitors to the booth will be offered Lotte Pepero, German beer, champagne, and other refreshments, providing an opportunity to communicate in a relaxed atmosphere, according to the company.

Lotte Biologics plans to further strengthen its position as a global CDMO by leveraging the advantages of its "Dual Site" strategy and "proven quality competitiveness" as core capabilities. In addition, the company aims to highlight to potential global clients, including those in Europe, that it is an optimal partner capable of responding to the recent reshoring trend in the United States.

James Park, CEO of Lotte Biologics, stated, "We will emphasize our role as an innovative partner capable of responding quickly and flexibly to market changes," adding, "Not only at this event, but also at upcoming international events such as the World ADC and the JP Morgan Healthcare Conference, we will further strengthen our global competitiveness through more proactive partnering."

This content was produced with the assistance of AI translation services.